Less than two weeks after China’s conditional approval of Sinopharm’s COVID-19 vaccine, the chairman and a director at the state-owned drug company suddenly resigned on the same day for “personal reasons.” The unexpected news fueled public speculation and doubts over the quality of the Chinese-made vaccine. On Jan. 12, Sinopharm Group Co. issued two consecutive announcements, stating that Li Zhiming, chairman of Sinopharm Holding Corporation, and Li Hui, director and general manager of Sinopharm Group Pharmaceutical Co., a subsidiary, have resigned due to “personal reasons.” The announcement also stated that the resignations will take effect immediately. The board of directors elected Yu Qingming as acting chairman on the same day. Since November 2018, Yu has served as executive director and secretary general of the Chinese Communist Party (CCP)’s committee within the company. Previously, he worked as the secretary to CCP officials of the National Medical Products Administration. In addition, the …